Cargando…
ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity
Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) blockade therapy is able to induce long-lasting antitumor responses in a fraction of cancer patients. Nonetheless, there is still room for improvement in the quest for new therapeutic combinations. ICOS costimulation has been underscored as a poss...
Autores principales: | Soldevilla, Mario Martínez, Villanueva, Helena, Meraviglia-Crivelli, Daniel, Menon, Ashwathi Puravankara, Ruiz, Marta, Cebollero, Javier, Villalba, María, Moreno, Beatriz, Lozano, Teresa, Llopiz, Diana, Pejenaute, Álvaro, Sarobe, Pablo, Pastor, Fernando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838990/ https://www.ncbi.nlm.nih.gov/pubmed/31405808 http://dx.doi.org/10.1016/j.ymthe.2019.07.013 |
Ejemplares similares
-
A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression
por: Meraviglia-Crivelli, Daniel, et al.
Publicado: (2022) -
IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction
por: Meraviglia-Crivelli, Daniel, et al.
Publicado: (2022) -
Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?
por: Sola, Mayte, et al.
Publicado: (2020) -
Aptamer-iRNAs as Therapeutics for Cancer Treatment
por: Soldevilla, Mario M., et al.
Publicado: (2018) -
Modulating T Cell Responses by Targeting CD3
por: Menon, Ashwathi Puravankara, et al.
Publicado: (2023)